(NASDAQ: COGT) Cogent Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.22%.
Cogent Biosciences's earnings in 2025 is -$294,372,000.On average, 15 Wall Street analysts forecast COGT's earnings for 2025 to be -$322,625,215, with the lowest COGT earnings forecast at -$337,660,176, and the highest COGT earnings forecast at -$278,061,361. On average, 14 Wall Street analysts forecast COGT's earnings for 2026 to be -$269,276,729, with the lowest COGT earnings forecast at -$336,264,886, and the highest COGT earnings forecast at -$146,505,448.
In 2027, COGT is forecast to generate -$132,951,203 in earnings, with the lowest earnings forecast at -$262,314,517 and the highest earnings forecast at $145,010,495.